The self-inspection and rectification transition period has ended, and the industry has entered a zero-tolerance strict inspection phase.
Starting July 1, 2026, the self-inspection and rectification transition period for the medical aesthetics industry officially ends, and the industry fully enters a new strict inspection phase with "zero buffer, zero tolerance." The "2026 Key Work Points for Correcting Unhealthy Trends in the Field of Pharmaceutical Purchasing and Medical Services," jointly issued by 14 ministries including the National Health Commission, the Ministry of Public Security, and the State Administration for Market Regulation, has brought the intensity of medical aesthetics industry rectification to an unprecedented level.
This is not merely a simple upgrade of regulation, but a key signal of industry reshuffling. For OEMs and manufacturers that adhere to compliance bottom lines, this precisely means new opportunities are arriving.
What exactly is being inspected this time? Full coverage of six areas
Unlike previous special rectification campaigns, this inspection covers six core areas including institutions and personnel, drugs and devices, technology, advertising, and services, forming closed-loop supervision across the entire chain.
In terms of institutional and personnel qualifications, focus is on verifying the validity period of practice licenses, whether diagnostic and treatment subjects exceed the approved scope, and whether medical staff practice certificates are registered with the institution. Separation of person and certificate, and non-medical-aesthetics specialty doctors performing plastic surgery injection projects, have long been chronic industry problems and are explicitly listed as key targets this time.
In terms of drug and device traceability, the procurement channels, purchase vouchers, and traceability ledgers of injectable consumables such as botulinum toxin and hyaluronic acid must be checked one by one. Smuggled goods, counterfeit products, and unlabeled products repackaged or blended face severe crackdowns. Photoelectric devices such as facial radiofrequency instruments must hold Class III medical device registration certificates; those without them must be discontinued.
In terms of advertising and promotion, short video platforms, Xiaohongshu seeding, store posters, and online group buying are all included in the inspection scope. Without medical advertising review qualifications, no promotional content may be published. Marketing methods such as before-and-after comparisons, exaggerated effects, creating appearance anxiety, and using patient cases as endorsements are strictly prohibited.
It is worth noting that the 14 departments have listed three major issues as key rectification targets: "providing medical aesthetics services without qualifications," "illegally conducting light medical aesthetics crash courses," and "false commercial marketing." This means that from upstream products to terminal services, the entire industry chain is within the regulatory vision.
Five types of violations directly expelled, higher fines of 500,000 yuan
After July 1, five types of violating institutions and individuals will be directly expelled from the market: those engaging in injection, photoelectric, or surgical medical aesthetics projects without qualifications will not only be expelled from the industry but also face fines of 30,000 to 100,000 yuan, with lifetime bans from the profession for serious cases. Those whose certificates expire without timely verification will be treated as unlicensed practice. For certificate affiliation and separation of person and certificate, both the physician and the institution involved will be punished, and serious cases will have their business licenses directly revoked. Non-medical-aesthetics specialty doctors practicing beyond scope or illegal black medical aesthetics studios operating illegally will face higher fines of 500,000 yuan and store closure. If illegal operations cause medical accidents, criminal liability will also be pursued.
This level of punishment is the first of its kind in the history of medical aesthetics regulation, sending a very clear signal: compliance is not a multiple-choice question, but a mandatory question for survival.
What does this mean for OEMs and manufacturers?
Stricter industry regulation appears on the surface to be a constraint, but in essence it is reshaping the market competition landscape. As non-compliant institutions and products are accelerated out of the market, the market space for compliant enterprises is actually expanding.
From the product side, the entry threshold for medical device-numbered products has been further raised. In June 2026, the National Medical Products Administration intensively issued multiple regulations: dynamic adjustment of the classification catalog has become routine, popular categories such as radiofrequency therapeutic instruments have been included in Class III management, the new GMP verification standards are open for comments, and full-chain UDI traceability has become a mandatory requirement. These changes place higher demands on manufacturers' quality management systems and registration application capabilities.
From the demand side, when medical aesthetics institutions choose cooperative OEMs, qualification compliance, complete licenses, and traceable quality will become leading considerations. Suppliers that survive on low prices and edge-ball tactics are being eliminated, while top OEMs with more than 110 Class II medical device registration filings, ISO13485 certification, and complete quality management systems are ushering in a trend of order concentration.
According to industry data, in the first half of 2026, the light medical aesthetics market continued to maintain double-digit growth, with non-surgical medical aesthetics services accounting for 47.4%. Consumers are shifting from "short-term results" to "long-term anti-aging," and from "exaggerated transformation" to "natural fine-tuning," with increasingly higher demands for product safety and efficacy. This shift in consumer logic is both a challenge and a benefit for upstream manufacturers.
Compliance capability building is long-term competitiveness
Facing the trend of normalized regulation, manufacturers need to continue investing in the following aspects:
Quality system upgrade. The draft of the new GMP for comments has greatly refined defect determination standards, with full-process UDI traceability, sterilization process validation, commissioned production management, and co-line clearance listed as core inspection items. Enterprises need to complete system upgrades according to the new standards, rather than waiting for unannounced inspections to make passive rectifications.
Registration certificate reserves. The transition period for classification adjustments is wrapping up, and existing products need to complete category switching as soon as possible. At the same time, new product R&D must fully consider the requirements of the new classification catalog to avoid rejection during application due to classification errors.
Compliance promotion system. The "first year of compliance" for online marketing has arrived. The live-streaming e-commerce management measures are deeply linked with the Advertising Law, and influencer sales of medical aesthetics products have been explicitly prohibited. Manufacturers' own product promotion, investment materials, and official website content all require comprehensive compliance review.
Traceability capability building. From raw material procurement to finished product delivery, full-chain traceability is not only a regulatory requirement but also a core competitiveness for winning the trust of brand customers.
The industry inflection point has arrived
The medical aesthetics industry in 2026 is undergoing a key turning point from野蛮 growth to standardized development. The joint rectification by 14 ministries is not the end, but a milestone in the industry's compliance process.
For top OEM enterprises like Weitai Group, which has done medical aesthetics functional skincare for many years—25 years—and owns four smart factories and more than 110 Class II medical device registration filings, stricter regulation is not a threat but a moat. When the tide goes out, truly capable enterprises will surface.
The next decade of the industry belongs to those enterprises that engrave compliance into their bones and pursue quality to the extreme.
About Weitai Group | OEM/ODM Contract Manufacturing Services
Weitai Group was founded in 2012, has done medical aesthetics functional skincare for many years—25 years—and is a medical aesthetics skincare OEM/ODM contract manufacturer with many years in the industry. Four factories (Guangzhou, Hunan, Zhaoqing) cover a total area of over 150,000 m², with 50+ fully automatic production lines, holding more than 110 Class II medical device registration filings, accumulating a mature formula library + mature formulas, and 72 patents.
Core contract manufacturing capabilities:
- Medical dressings/masks (daily output 1 million pieces, Class II medical device certificate)
- Freeze-dried powder (daily output 1 million pairs, developed by own R&D laboratory)
- Essence serums/lotions and creams (full category of cosmetic license numbers)
- Medical gels/hemostatic materials (Class II medical device certificate)
Quality assurance: US GMPC + EU ISO22716 dual certification, 38 quality inspections, yield rate 99.99%. Has served hundreds of brands (including Chando, etc.).
Cooperation models: OEM processing with supplied materials | ODM private label customization | Shitaqi spot direct supply
Delivery capability: Regular 7-15 days, expedited 3-day shipment. Official website: www.weitaigd.com